Minireview: RET: Normal and abnormal functions

被引：138
作者：
Santoro, M [1 ]
Melillo, RM [1 ]
Carlomagno, F [1 ]
Vecchio, G [1 ]
Fusco, A [1 ]
机构：
[1] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy
来源：
ENDOCRINOLOGY | 2004年 / 145卷 / 12期
关键词：
D O I：
10.1210/en.2004-0922
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The RET gene encodes a single-pass transmembrane receptor tyrosine kinase. RET is the oncogene that causes papillary thyroid carcinoma and medullary thyroid carcinoma. The latter may arise as a component of multiple endocrine neoplasia type 2 syndromes; germline mutations in RET are responsible for multiple endocrine neoplasia type 2 inheritance. In this report we review data on the mechanisms leading to RET oncogenic conversion and on RET targeting as a strategy in thyroid cancer treatment.
引用
收藏
页码：5448 / 5451
页数：4
相关论文
共 44 条
  • [1] The GDNF family: Signalling, biological functions and therapeutic value
    Airaksinen, MS
    Saarma, M
    [J]. NATURE REVIEWS NEUROSCIENCE, 2002, 3 (05) : 383 - 394
  • [2] Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas
    Bender, BU
    Gutsche, M
    Gläsker, S
    Müller, B
    Kirste, G
    Eng, C
    Neumann, HPH
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (12) : 4568 - 4574
  • [3] Oncogenic kinase signalling
    Blume-Jensen, P
    Hunter, T
    [J]. NATURE, 2001, 411 (6835) : 355 - 365
  • [4] Guidelines for diagnosis and therapy of MEN type 1 and type 2
    Brandi, ML
    Gagel, RF
    Angeli, A
    Bilezikian, JP
    Beck-Peccoz, P
    Bordi, C
    Conte-Devolx, B
    Falchetti, A
    Gheri, RG
    Libroia, A
    Lips, CJM
    Lombardi, G
    Mannelli, M
    Pacini, F
    Pondder, BAJ
    Raue, F
    Skogseid, B
    Tamburrano, G
    Thakker, RV
    Thompson, NW
    Tomassetti, P
    Tonelli, F
    Wells, SA
    Marx, SJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) : 5658 - 5671
  • [5] Molecular diagnosis of multiple endocrine neoplasia Type 2
    Bugalho, MJ
    Domingues, R
    Sobrinho, L
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2003, 3 (06) : 769 - 779
  • [6] Carlomagno F, 2002, CANCER RES, V62, P7284
  • [7] Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors
    Carlomagno, F
    Guida, T
    Anaganti, S
    Vecchio, G
    Fusco, A
    Ryan, AJ
    Billaud, M
    Santoro, M
    [J]. ONCOGENE, 2004, 23 (36) : 6056 - 6063
  • [8] Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2)
    Carlomagno, F
    Vitagliano, D
    Guida, T
    Basolo, F
    Castellone, MD
    Melillo, RM
    Fusco, A
    Santoro, M
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (04) : 1897 - 1902
  • [9] Carlomagno F, 2002, CANCER RES, V62, P1077
  • [10] Carniti C, 2003, CANCER RES, V63, P2234
12345